Generic Name and Formulations:
Alcaftadine 0.25%; oph soln; contains benzalkonium chloride.
Indications for LASTACAFT:
Prevention of ocular itching associated with allergic conjunctivitis.
Adults and Children:
<2yrs: not established. ≥2yrs: 1 drop in each eye once daily.
Contact lenses (remove; may reinsert 10 mins after administration, if eye is not red). Pregnancy (Cat.B). Nursing mothers.
H1 histamine receptor antagonist.
Ocular effects (eg, irritation, burning/stinging, redness, pruritus), nasopharyngitis, headache.
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Congress Passes Bill to Fight Opioid Crisis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure